Loading
Latest filing published 06 Nov 2025 for Relmada Therapeutics, INC., €261k. Read the official filing
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Chuck Ence discloses dealings in Relmada Therapeutics, Inc. to SEC (Form 4). The record holds 3 filings, for trades running from 29 January 2024 to 5 November 2025.
On the market, this insider has only ever bought: 3 purchases, €389k in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2025 to date brings 2 purchases and no sales.
Half of the purchases are above €92k and half below. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 67% of cases, with a median move of +19.7%. These figures describe past trades and do not predict future prices.
The newest entry dates from 6 November 2025: an open-market purchase of €261k, in Relmada Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations